Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ernexa Therapeutics (ERNA) EBT Margin (2016 - 2024)

Historic EBT Margin for Ernexa Therapeutics (ERNA) over the last 14 years, with Q4 2024 value amounting to 30357.89%.

  • Ernexa Therapeutics' EBT Margin fell 177925900.0% to 30357.89% in Q4 2024 from the same period last year, while for Sep 2025 it was 96484.21%, marking a year-over-year decrease of 893543700.0%. This contributed to the annual value of 7421.5% for FY2024, which is 142495000.0% up from last year.
  • Ernexa Therapeutics' EBT Margin amounted to 30357.89% in Q4 2024, which was down 177925900.0% from 5460.37% recorded in Q3 2024.
  • Ernexa Therapeutics' 5-year EBT Margin high stood at 24271.43% for Q2 2022, and its period low was 30357.89% during Q4 2024.
  • Over the past 4 years, Ernexa Therapeutics' median EBT Margin value was 5460.37% (recorded in 2024), while the average stood at 5417.51%.
  • As far as peak fluctuations go, Ernexa Therapeutics' EBT Margin crashed by -225120500bps in 2023, and later skyrocketed by 55180600bps in 2024.
  • Over the past 4 years, Ernexa Therapeutics' EBT Margin (Quarter) stood at 216.68% in 2020, then surged by 11301bps to 24271.43% in 2022, then plummeted by -152bps to 12565.31% in 2023, then tumbled by -142bps to 30357.89% in 2024.
  • Its EBT Margin stands at 30357.89% for Q4 2024, versus 5460.37% for Q3 2024 and 11757.45% for Q2 2024.